viewLexaria Bioscience Corp.

Lexaria Bioscience shareholders approve the appointment of four directors

Shareholders approved all matters at the annual general meeting, including the appointment of Davidson & Company LLP as auditor

lab extracts
Lexaria's DehydraTECH technology can be applied to foods, beverages, cannabis, oral suspensions, tablets and capsules

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) reported a successful annual general meeting Friday, noting all matters were approved, including the appointment of four directors. 

The firm said directors appointed included: Chris Bunka, John Docherty, Nicholas Baxter and Ted McKechnie. The firm noted Davidson & Company LLP has been appointed as auditor. 

READ: Lexaria Bioscience crafts new DehydraTECH innovation, files patents

The firm noted shareholders also approved executive compensation.

Lexaria has developed and out-licenses its delivery technology, which promotes healthier ingestion methods and lower overall dosing. Its DehydraTECH technology is essentially a delivery system that allows drugs and vitamins to get into the bloodstream quicker, while making them taste and smell better at the same time. The firm acquired its technology in 2014. 

Lexaria's technology provides boosts in intestinal absorption rates and more rapid bloodstream delivery for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine and other molecules.

The firm has patents pending in more than 40 countries.

Shares of Lexaria Bioscience were at C$1.10 on Friday. 

Contact Katie Lewis at katie@proactiveinvestors.com

Quick facts: Lexaria Bioscience Corp.

Price: 0.245 CAD

Market: CSE
Market Cap: $22.06 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...


Lexaria receives ethics board ok to launch human study with DehydraTech for...

Lexaria Bioscience (CSE: LXX-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive with news the company has received ethics board approval to conduct a pilot human pharmacokinetic exploratory study of antiviral drugs that have previously been studied against other coronavirus...

4 weeks, 1 day ago

2 min read